Cannabis and Schedule III: The Complete 2026 Communications Guide

Originally published May 2026. Updated October 2026 with the post-hearing status, the revised hemp effective dates, and the operator communications framework.

By EPR Editorial Team

Inside EPR's Cannabis coverage. This is the canonical Schedule III reference: regulatory mechanics, investor narrative, communications strategy, and the marketing playbook in one place.

Cannabis Schedule III communications is the work of explaining one narrow federal change accurately. Since the April 2026 order, state-licensed medical marijuana and FDA-approved marijuana products sit in Schedule III, while adult-use cannabis stays in Schedule I pending a DEA ruling. Operators should publish what the order changed, what it did not change, and what depends on the pending decision.

What did the Schedule III order change for cannabis?

The April 2026 order, signed by Attorney General Todd Blanche, moved two groups of products from Schedule I to Schedule III: FDA-approved drug products containing marijuana (Epidiolex, Marinol, Syndros, and Cesamet) and marijuana products regulated under a qualifying state medical license. It was issued under treaty-implementation authority (21 U.S.C. § 811(d)(1)), citing U.S. obligations under the Single Convention on Narcotic Drugs, after President Trump's December 18, 2025 executive order on medical marijuana and CBD research.

The order does not legalize recreational marijuana federally. It does not affect synthetically derived THC or hemp, alter VHA Directive 1315 (VA doctors still cannot recommend medical marijuana), or override state prohibition. It does not lift advertising restrictions on Meta, Google, or TikTok, which are platform policies independent of federal scheduling. Federal employee and military drug-testing frameworks are unchanged.

Section 280E of the Internal Revenue Code is the largest commercial change. Cannabis operators have been barred from deducting ordinary business expenses, including marketing, branding, and agency fees, which produced effective federal tax rates that frequently exceeded 70% of EBITDA. Schedule III removes that penalty for qualifying medical operators, and the Cannabis Regulators Association estimates effective rates could fall to roughly 20-30%. A 60-day DEA registration window, which closed June 22, 2026, let state-licensed medical operators file paperwork to preserve protected operating status. The DOJ has encouraged Treasury to consider retroactive 280E relief, but the IRS has not issued formal guidance.

Where does the DEA adult-use rescheduling decision stand?

The DEA evidentiary hearing on moving adult-use marijuana to Schedule III ran from June 29 to July 15, 2026, across 11 hearing days. Chief Administrative Law Judge Derek Julius set an August 17 deadline for post-hearing briefs, after which he issues a recommended decision. DEA Administrator Terry Cole then makes the final ruling, and the DEA has published the 2,533-page hearing transcript.

Until that ruling arrives, adult-use cannabis remains in Schedule I. Legal challenges to the use of treaty authority for the April order are expected, so operators should plan for a decision that can be appealed.

When does the new federal hemp definition take effect?

Portions of the new federal hemp definition now take effect December 11, 2026, after Congress delayed them from November 12. The exclusion of cannabinoids that a cannabis plant cannot naturally produce still takes effect November 12, 2026, according to the Congressional Research Service's September 28, 2026 update. For the brand-side response to the delay, see Hemp THC Ban Delay: What CBD Brands Should Do Now.

The definition comes from the Continuing Appropriations Act, 2026 (P.L. 119-37), signed November 12, 2025. It applies the 0.3% dry-weight limit to total THC, including THCA, caps finished hemp products at 0.4 mg of total THC per container, and excludes synthesized cannabinoids. Together these changes are expected to push most THCA flower, intoxicating gummies, vapes, and beverages outside the legal hemp definition.

The stakes are large. Industry figures cited by Rep. James Comer (R-KY) place the hemp economy at roughly $28 billion in market activity, 320,000 jobs, and $1.5 billion in state tax revenue, and the U.S. Hemp Roundtable estimates about 95% of intoxicating-hemp products could leave the market. Rep. Jim Baird's H.R. 7010 would move the effective date to November 12, 2028, and the House-passed 2026 Farm Bill kept the intoxicating-hemp restrictions. Enforcement capacity at FDA and DEA is limited, so civil litigation from licensed operators against hemp-derived competitors may move faster than agency action.

Which federal agencies shape cannabis communications?

Seven federal agencies touch the cannabis category from different angles, and each has its own communications implications. State enforcement adds a further layer through state cannabis control boards, attorneys general, departments of agriculture for hemp, and tribal regulatory bodies, so communications planning has to account for at least three regulatory levels at once on every campaign and every crisis response.

• Drug Enforcement Administration (DEA). Scheduling authority under the Controlled Substances Act. The pending decision on broader rescheduling sits here.
• U.S. Food and Drug Administration (FDA). Authority over health claims, drug labeling, food-additive status and dietary supplement classification. FDA warning letters are a major source of cannabis and CBD enforcement risk on the communications side.
• U.S. Department of Agriculture (USDA). Hemp regulation under the 2018 Farm Bill, which set the 0.3% Delta-9 THC threshold defining federally legal hemp.
• Department of the Treasury and FinCEN. Bank Secrecy Act enforcement and the FinCEN 2014 guidance defining how banks may serve state-legal cannabis operators. See the SAFE Banking communications playbook.
• Federal Trade Commission (FTC). Advertising substantiation, endorsement disclosure and unfair or deceptive practices oversight.
• Internal Revenue Service (IRS). Section 280E denies deductions to businesses trafficking in Schedule I or II substances. Schedule III status sits outside that language, but whether an operator benefits depends on its products and counsel.
• Securities and Exchange Commission (SEC). Public-company disclosure standards for U.S. and Canadian-listed multi-state operators.

How has the investor narrative changed since Schedule III?

Cannabis investors now price tax relief and medical integration instead of a legalization-growth story. Section 280E relief for state-licensed medical operators moves effective tax rates toward market standard, and Schedule III status places those operators inside a recognized federal pharmaceutical framework, with implications for capital sources, insurance coverage, banking relationships, and acquirer interest.

Two further shifts follow. The hemp definition change is expected to reduce unlicensed-channel competition, which combined with 280E relief sets up possible multi-state operator consolidation. Epidiolex, Marinol, Syndros, and Cesamet remain the only FDA-approved products in the category, but the pharma pipeline becomes more credible under Schedule III.

The public multi-state operator tier includes Curaleaf Holdings, Trulieve, Green Thumb Industries, Cresco Labs, Verano Holdings, Ascend Wellness, and TerrAscend. Canadian-listed operators with U.S. exposure include Tilray, Canopy Growth, and Cronos Group, and cannabis REITs such as Innovative Industrial Properties and NewLake Capital Partners provide sale-leaseback capital.

How should operators run Schedule III communications?

Operators should run Schedule III communications across five audiences: investors, regulators, patients and consumers, trade press, and mainstream business press. Each audience asks different questions, so one press release does not serve all five.

What should operators tell investors?

Investors need quantified, scenario-based disclosure. Publish a sensitivity analysis showing performance under each possible DEA outcome and a capital allocation framework that adjusts to each. Position the business to work without further policy change, treat medical-only Schedule III as the floor, and present adult-use rescheduling and SAFER Banking as upside. See the SAFE Banking communications playbook.

What should operators tell regulators?

Regulators respond to substantive, specific input. File comments on DEA rulemaking, document compliance practices, and engage state regulators on implementation.

What should operators tell patients and consumers?

Patients and consumers want plain-language answers about medical access, insurance treatment, product availability, pricing, and retail channels. Publish explainers on what rescheduling does and does not change for them.

What should operators tell trade press?

Trade press needs original analysis it can cite and an operator who answers the phone during decision windows. Operators that go quiet while a ruling is pending leave the commentary to competitors.

What should operators tell mainstream business press?

Bloomberg, the Wall Street Journal, Reuters, and CNBC cover cannabis rarely, so prepare specific data and analytical commentary before a ruling lands. The same preparation supports the 280E story.

What should every operator publish before the DEA ruling?

Every plant-touching operator should have five documents live before the DEA issues its ruling on adult-use cannabis. These documents give reporters, investors, and AI answer engines a primary source to cite instead of secondhand summaries.

1. A one-page Schedule III impact statement covering what the April order changed, what further rescheduling would change, and what stays the same under each scenario.
2. A medical and adult-use revenue split by state for the current quarter, which is the data point investors need to size 280E exposure.
3. A DEA registration progress report listing filings by state, the status of each, and expected completion.
4. A capital allocation framework stating what the operator will do with 280E relief, with specific uses and time frames.
5. A scenario analysis showing the business under medical-only persistence, expanded medical, full Schedule III for adult-use, and no further movement.

Which mistakes cost operators coverage during a regulatory decision?

Three patterns cost operators coverage during a regulatory decision: going quiet, over-promising, and speaking only to investors.

• Operators that cut communications volume during a high-stakes decision window leave the commentary to competitors and trade press.
• Operators that present a favorable outcome as certain lose credibility with analysts when the ruling differs.
• Operators that address only investors miss the patients, consumers, trade reporters, and regulators who ask different questions in the same window.

What changes in cannabis marketing after Schedule III?

Schedule III changes the tax treatment of marketing for qualifying medical operators, because 280E no longer disallows those deductions. It does not unlock paid advertising on Google, Meta, or TikTok, which remain platform-level policies. Anyone pitching new Meta campaigns because cannabis is Schedule III is misinformed. Five channels still do the work:

1. Generative engine optimization (GEO). Consumers researching dispensaries or products get answers from ChatGPT, Perplexity, and Google AI Overviews before they click, so a brand that is not cited inside the answer is missing at the research stage.
2. Earned media in authority press. Answer engines pull from indexed publishers, so a mention in a high-authority trade or business outlet feeds traditional search, AI Overview citations, and model training at once.
3. Owned channels, email and SMS. No platform risk and no ad bans. See email marketing in cannabis.
4. Compliant influencer marketing, with explicit disclosure, age-gated audiences, no health claims, and certificate-of-analysis substantiation. See how cannabis brands win with influencers in 2026.
5. Connected TV and digital out-of-home, with geofencing and 21+ targeting where state rules allow.

This quarter's checklist: file DEA registration if you are a state-licensed medical operator, audit owned-channel data (email list health, SMS opt-in compliance, first-party data), and run category prompts across ChatGPT, Perplexity, Gemini, and Google AI Mode. If competitors are cited and your brand is not, that gap is a bigger revenue risk than most licensing issues. EPR's Cannabis Index tracks which brands AI engines cite.

What should cannabis operators watch next?

• The administrative law judge's recommended decision and the DEA Administrator's final ruling on adult-use rescheduling
• November 12, 2026, when the exclusion of synthesized cannabinoids takes effect
• December 11, 2026, when the delayed portions of the new hemp definition take effect
• Treasury and IRS guidance on 280E for state-licensed medical operators
• Litigation challenging the use of treaty authority for the April order
• Multi-state operator M&A as 280E relief changes balance sheets

Related EPR Coverage

• EPR Cannabis hub
• The Cannabis Index: Who Owns the AI Answer in 2026
• The SAFE Banking Communications Playbook
• Hemp Is a $38.5B Category. Nobody Owns It.
• Hemp PR Is Legal Exposure Work
• Hemp THC Ban Delay: What CBD Brands Should Do Now